Sausville EA - Search Results

1

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM. Lam LT, et al. Among authors: sausville ea. Genome Biol. 2001;2(10):RESEARCH0041. doi: 10.1186/gb-2001-2-10-research0041. Epub 2001 Sep 13. Genome Biol. 2001. PMID: 11597333 Free PMC article.

2

Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.

Monks A, Harris E, Hose C, Connelly J, Sausville EA. Monks A, et al. Among authors: sausville ea. Mol Pharmacol. 2003 Mar;63(3):766-72. doi: 10.1124/mol.63.3.766. Mol Pharmacol. 2003. PMID: 12606787

3

The hollow fibre model in cancer drug screening: the NCI experience.

Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA. Decker S, et al. Among authors: sausville ea. Eur J Cancer. 2004 Apr;40(6):821-6. doi: 10.1016/j.ejca.2003.11.029. Eur J Cancer. 2004. PMID: 15120037

4

Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.

Gitler MS, Monks A, Sausville EA. Gitler MS, et al. Among authors: sausville ea. Mol Cancer Ther. 2003 Sep;2(9):929-32. Mol Cancer Ther. 2003. PMID: 14555712 No abstract available.

5

Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.

Hose CD, Hollingshead M, Sausville EA, Monks A. Hose CD, et al. Among authors: sausville ea. Mol Cancer Ther. 2003 Dec;2(12):1265-72. Mol Cancer Ther. 2003. PMID: 14707267

6

Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation.

Hose C, Kaur G, Sausville EA, Monks A. Hose C, et al. Among authors: sausville ea. Clin Cancer Res. 2005 Sep 1;11(17):6370-81. doi: 10.1158/1078-0432.CCR-05-0291. Clin Cancer Res. 2005. PMID: 16144942

7

Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.

Wallqvist A, Connelly J, Sausville EA, Covell DG, Monks A. Wallqvist A, et al. Among authors: sausville ea. Mol Pharmacol. 2006 Mar;69(3):737-48. doi: 10.1124/mol.105.017061. Epub 2005 Dec 6. Mol Pharmacol. 2006. PMID: 16332985

8

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW. O'Connor PM, et al. Among authors: sausville ea. Cancer Res. 1997 Oct 1;57(19):4285-300. Cancer Res. 1997. PMID: 9331090

9

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connelly JW, Sausville EA. Monks A, et al. Among authors: sausville ea. Invest New Drugs. 2000 May;18(2):95-107. doi: 10.1023/a:1006313611677. Invest New Drugs. 2000. PMID: 10857990

10

A potential role for imaging technology in anticancer efficacy evaluations.

Hollingshead MG, Bonomi CA, Borgel SD, Carter JP, Shoemaker R, Melillo G, Sausville EA. Hollingshead MG, et al. Among authors: sausville ea. Eur J Cancer. 2004 Apr;40(6):890-8. doi: 10.1016/j.ejca.2003.12.018. Eur J Cancer. 2004. PMID: 15120044

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

353 results

Search Page